The use of VEN for clinical management of CLL and AML is a key milestone since the discovery of BH3-mimetic Bcl-2 inhibitor(s); however, relapse occurs due to the upregulation of a different anti-apoptotic protein Mcl-1 and switch in survival dependence. Here, BCL2 is linked to acute myeloid leukemia.